Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HY-PAM "25" vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Symptomatic relief of anxiety and tension associated with psychoneurosis,Adjunct in organic disease states with anxiety,Pruritus due to allergic conditions such as chronic urticaria, atopic and contact dermatoses
Hypertension
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (Cr Cl <30 m L/min) and in elderly patients.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Primarily hepatic via CYP3A4 and CYP2D6 isoenzymes; major metabolite is cetirizine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
95-98% bound to albumin and alpha-1-acid glycoprotein.
~90%, primarily to albumin
0.2-0.3 L/kg, indicating primarily plasma and extracellular fluid distribution.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 60-70% (due to first-pass metabolism); Rectal: 80-90%; Intramuscular: 100%.
Oral: 50–60% (extensive first-pass metabolism)
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific dose recommendation available.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
For Child-Pugh Class A or B, dose reduction to 12.5 mg daily may be considered due to increased exposure; avoid use in Child-Pugh Class C (severe hepatic impairment).
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not established; contraindicated in pediatric patients due to lack of safety and efficacy data.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at 12.5 mg daily; maximum dose 25 mg daily due to increased sensitivity and risk of falls, cognitive impairment, and adverse effects.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
May cause QT prolongation, especially in patients with risk factors,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Central nervous system depressant effects may impair mental or physical abilities,Avoid concurrent use with alcohol or other CNS depressants,Use with caution in elderly patients due to increased sensitivity and anticholinergic effects
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to hydroxyzine or any component,Early pregnancy (first trimester) due to potential fetal harm,Porphyria (may precipitate attacks),Concomitant use with monoamine oxidase inhibitors
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
No significant food interactions known.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
HY-PAM 25 is a benzodiazepine. First trimester: Data suggest an increased risk of oral clefts (approximately 0.6% vs 0.4% background). Second trimester: Possible risk of other malformations, but data are limited. Third trimester: Chronic use may cause neonatal withdrawal, floppy infant syndrome (hypotonia, lethargy, feeding difficulties), and respiratory depression at delivery.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Benzodiazepines like HY-PAM 25 are excreted in breast milk. The M/P ratio is approximately 0.5-0.7. With short-acting agents and moderate doses, risk to infant is low but monitor for sedation and poor feeding. Avoid breastfeeding if high maternal doses or chronic use; consider alternative agent.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Increased clearance and volume of distribution in pregnancy may require dose adjustment. For HY-PAM 25, consider increasing the dose by 20-30% in third trimester to maintain efficacy, but taper postpartum to avoid accumulation. Use lowest effective dose and avoid chronic use.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
HY-PAM '25' is a compounded topical formulation containing hydrocortisone 2.5%, pramoxine 1%, and aluminum acetate 0.25%. Use for acute inflammatory dermatoses with pruritus and exudation. Avoid prolonged use on intertriginous areas. Discontinue if signs of skin atrophy or secondary infection develop.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Apply a thin layer to affected areas 3-4 times daily.,Do not use on broken skin, deep wounds, or infected skin without medical guidance.,Avoid contact with eyes and mucous membranes.,Do not cover with bandages or dressings unless directed by your doctor.,Report any worsening of rash, burning, or signs of skin thinning.,Do not use for more than 2 weeks unless directed by your doctor.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HY-PAM "25" vs ALDORIL 15, answered by our medical review team.
HY-PAM "25" is a Antihypertensive Combination that works by Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HY-PAM "25" and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HY-PAM "25" is: 25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HY-PAM "25" and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HY-PAM "25" is classified as Category C. HY-PAM 25 is a benzodiazepine. First trimester: Data suggest an increased risk of oral clefts (approximately 0.6% vs 0.4% background). Second trimester: Possible risk of other malf. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.